NO20065757L - Purinderivater - Google Patents

Purinderivater

Info

Publication number
NO20065757L
NO20065757L NO20065757A NO20065757A NO20065757L NO 20065757 L NO20065757 L NO 20065757L NO 20065757 A NO20065757 A NO 20065757A NO 20065757 A NO20065757 A NO 20065757A NO 20065757 L NO20065757 L NO 20065757L
Authority
NO
Norway
Prior art keywords
purine derivatives
formula
adenosine
solvates
agonists
Prior art date
Application number
NO20065757A
Other languages
English (en)
Inventor
Derek Norman Evans
Philip Blatcher
Richard Peter Charles Cousins
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0411563A external-priority patent/GB0411563D0/en
Priority claimed from GB0509521A external-priority patent/GB0509521D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20065757L publication Critical patent/NO20065757L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer en forbindelse med formel (I) og salter og solvater derav. Forbindelser med formel (I) er agonister av adenosin A2A reseptoren og antas å ha potensiell anvendelse ved behandlingen av inflammatoriske sykdommer så som astma og kronisk obstruktiv lungesykdom.
NO20065757A 2004-05-24 2006-12-13 Purinderivater NO20065757L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0411563A GB0411563D0 (en) 2004-05-24 2004-05-24 Compounds
GB0509521A GB0509521D0 (en) 2005-05-10 2005-05-10 Compounds
PCT/EP2005/005651 WO2005116037A1 (en) 2004-05-24 2005-05-23 Purine derivative

Publications (1)

Publication Number Publication Date
NO20065757L true NO20065757L (no) 2006-12-13

Family

ID=34968031

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065757A NO20065757L (no) 2004-05-24 2006-12-13 Purinderivater

Country Status (16)

Country Link
US (1) US7737126B2 (no)
EP (1) EP1756120B1 (no)
JP (1) JP5007225B2 (no)
AR (1) AR049384A1 (no)
AT (1) ATE556080T1 (no)
AU (1) AU2005247601A1 (no)
BR (1) BRPI0511424A (no)
CA (1) CA2566863A1 (no)
ES (1) ES2383604T3 (no)
IL (1) IL179009A0 (no)
MA (1) MA28611B1 (no)
MX (1) MXPA06013627A (no)
NO (1) NO20065757L (no)
PE (1) PE20060272A1 (no)
RU (1) RU2006141276A (no)
WO (1) WO2005116037A1 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0514809D0 (en) * 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
GB0523778D0 (en) * 2005-11-23 2006-01-04 Glaxo Group Ltd Novel method
GB0523845D0 (en) * 2005-11-23 2006-01-04 Glaxo Group Ltd Novel salts
US20090163723A1 (en) * 2005-11-25 2009-06-25 Hideki Kimura Method for producing sulfonium fluorinated alkylfluorophosphate
PE20071068A1 (es) 2005-12-20 2007-12-13 Glaxo Group Ltd Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
US8258141B2 (en) 2006-04-21 2012-09-04 Novartis Ag Organic compounds
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
EP1889846A1 (en) * 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
KR20090087054A (ko) * 2006-11-10 2009-08-14 노파르티스 아게 시클로펜텐 디올 모노아세테이트 유도체

Family Cites Families (204)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE768925A (fr) 1970-06-30 1971-11-03 Takeda Chemical Industries Ltd Derives d'adenosine et procede de preparation
DE2034785A1 (de) 1970-07-14 1972-01-20 Boehnnger Mannheim GmbH, 6800 Mann heim Waldhof Adenosin 5 carbonsäurederivate
CA1019727A (en) 1971-03-18 1977-10-25 Abbott Laboratories Adenosine-5'-carboxylic acid amides
BE789773A (fr) * 1971-10-08 1973-04-06 Schering Ag Adenosines n6 -substituees et leur procede de
US3864483A (en) * 1972-03-22 1975-02-04 Abbott Lab Adenosine-5{40 -carboxylic acid amides
CA1082695A (en) 1972-04-10 1980-07-29 Francis E. Fischer Process for preparing adenosine-5'-carboxamides
US3966917A (en) * 1974-07-30 1976-06-29 Abbott Laboratories Platelet aggregation inhibitors
DE2621470A1 (de) 1976-05-14 1977-12-01 Pharma Waldhof Gmbh & Co Nucleosidcarbonsaeurenitrile und ihre derivate, und verfahren zu ihrer herstellung
US4167565A (en) * 1976-11-08 1979-09-11 Abbott Laboratories Adenosine-5'-carboxamides and method of use
AU8379182A (en) 1981-06-04 1982-12-09 Procter & Gamble Company, The Composition of salicylates and purine derivatives
CA1239397A (en) 1983-08-01 1988-07-19 James A. Bristol N.sup.6-substituted adenosines
DE3406533A1 (de) * 1984-02-23 1985-08-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten
JPH0655756B2 (ja) * 1984-04-18 1994-07-27 ネルソン・リサ−チ・アンド・デベロツプメント・カンパニ− 心臓血管拡張薬としてのｎ−６置換アデノシン誘導体
US5310731A (en) 1984-06-28 1994-05-10 Whitby Research, Inc. N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents
CA1254888A (en) 1984-10-26 1989-05-30 Bharat Trivedi N.sup.6-bicycloadenosines
AU575438B2 (en) 1984-10-26 1988-07-28 Warner-Lambert Company N6 - substituted deoxyribose analogues of adenosines
US4663313A (en) * 1984-10-26 1987-05-05 Warner-Lambert Company N6 -tricyclic adenosines for treating hypertension
US4738954A (en) 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
US4755594A (en) 1986-01-31 1988-07-05 Warner-Lambert Company N6 -substituted adenosines
US5106837A (en) * 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
JPH0696534B2 (ja) * 1986-04-25 1994-11-30 ヘキストジヤパン株式会社 抗痴呆剤
US4767747A (en) * 1986-08-28 1988-08-30 Warner-Lambert Company Method for treating congestive heart failure with N6 -acenaphthyl adenosine
AU8276187A (en) 1986-10-31 1988-05-25 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
AU8274187A (en) 1986-10-31 1988-05-25 Warner-Lambert Company Heteroaromatic derivatives of adenosine
NL8702926A (nl) 1986-12-15 1988-07-01 Sandoz Ag Nieuwe furanuronzuurderivaten en werkwijzen voor het bereiden en toepassen van deze derivaten.
EP0277917A3 (en) 1987-02-04 1990-03-28 Ciba-Geigy Ag Certain adenosine 5'-carboxamide derivatives
US4968697A (en) * 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
US4962194A (en) * 1987-04-02 1990-10-09 Warner-Lambert Company Method of preparing 51,N6-disubstituted adenosines from inosines
LU87181A1 (fr) 1987-04-06 1988-11-17 Sandoz Sa Nouveaux derives de l'acide furannuronique,leur preparation et leur utilisation comme medicaments
US5219840A (en) * 1987-04-06 1993-06-15 Sandoz Ltd. Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives
JPH0725785B2 (ja) * 1989-01-11 1995-03-22 日本臓器製薬株式会社 アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物
US5646128A (en) * 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
IE903747A1 (en) 1989-10-19 1991-04-24 Searle & Co Method of treating gastrointestinal motility disorders
US5055569A (en) 1989-10-19 1991-10-08 G. D. Searle & Co. N-(6)-substituted adenosine compounds
ATE271064T1 (de) 1990-01-11 2004-07-15 Isis Pharmaceuticals Inc Oligonukleotidderivate zur detektieren und modulation von rna aktivität und genexpression
US5140015A (en) 1990-02-20 1992-08-18 Whitby Research, Inc. 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US5280015A (en) * 1990-09-05 1994-01-18 The United States Of America As Represented By The Department Of Health And Human Services 2-substituted adenosines and 2-substituted adenosine 5'-carboxamides
DE69123974T2 (de) 1990-09-25 1997-05-07 Rhone Poulenc Rorer Int Verbindungen welche antihypertensive und antiischemische eigenschaften besitzen
CA2100863A1 (en) 1991-01-23 1992-07-24 David A. Bullough Adenosine kinase inhibitors
GB9127376D0 (en) 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
FR2685918B1 (fr) 1992-01-08 1995-06-23 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
FR2687678B1 (fr) * 1992-01-31 1995-03-31 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
EP0633776B1 (en) 1992-04-02 2001-05-09 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
US5424297A (en) * 1992-04-27 1995-06-13 University Of Virginia Alumni Patents Foundation Adenosine dextran conjugates
AU4772493A (en) 1992-07-15 1994-02-14 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Sulfo-derivatives of adenosine
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
WO1994018215A1 (en) 1993-02-03 1994-08-18 Gensia, Inc. Adenosine kinase inhibitors comprising lyxofuranosyl derivatives
IL108523A0 (en) 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
AU7331094A (en) 1993-07-13 1995-02-13 United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The A3 adenosine receptor agonists
US5446046A (en) 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
WO1995018817A1 (fr) 1994-01-07 1995-07-13 Laboratoires Upsa Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant
ATE229001T1 (de) 1994-06-15 2002-12-15 Wellcome Found Zwischenprodukte verwendbar in der herstellung von enzym-inhibitoren
GB9414193D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
GB9414208D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
WO1996036729A1 (en) * 1995-05-18 1996-11-21 Coulter International Corp. An assay reagent and a method of making and using the assay reagent
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US5789589A (en) 1996-04-22 1998-08-04 Drug Innovation & Design, Inc. Guanine analog phosphates
AU3255097A (en) 1996-07-05 1998-02-02 Novo Nordisk A/S Novel (n)-alkoxyadenine derivatives acting as cytokine inhibitors
UA51716C2 (uk) 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
AU4377397A (en) 1996-10-14 1998-05-11 Novo Nordisk A/S Novel therapeutically active adenosine derivatives
TW528755B (en) * 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
WO1998030900A2 (en) * 1997-01-06 1998-07-16 Klaus Trier Aps Screening method for compounds active in treating myopia and hypermetropia
MY117948A (en) 1997-01-13 2004-08-30 Glaxo Group Ltd Nitride oxide synthase inhibitors.
DE19723722A1 (de) 1997-05-30 1998-12-10 Schering Ag Nichtsteroidale Gestagene
WO1999016766A1 (fr) 1997-10-01 1999-04-08 Kyowa Hakko Kogyo Co., Ltd. Derives de benzodioxole
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
US6506766B1 (en) 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
CO4990969A1 (es) 1998-02-14 2000-12-26 Glaxo Group Ltd Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol
PT1070056E (pt) 1998-03-14 2004-11-30 Altana Pharma Ag Inibidores de pde iii/iv a base de ftalazinona
GB9811599D0 (en) 1998-05-30 1998-07-29 Glaxo Group Ltd Nitric oxide synthase inhibitors
GB9813565D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813540D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
ATE246701T1 (de) 1998-06-23 2003-08-15 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivate
MY121142A (en) 1999-02-23 2005-12-30 Smithkline Beecham Corp Controlled release formulation for treating copd
EP1175422A2 (en) 1999-05-04 2002-01-30 Ligand Pharmaceuticals Incorporated Tetracyclic progesterone receptor modulator compounds and methods
ATE303387T1 (de) * 1999-07-02 2005-09-15 Eisai Co Ltd Kondensierte imidazolderivate und arzneimittel gegen diabetes mellitus
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US6263209B1 (en) 1999-07-28 2001-07-17 Motorola, Inc. Method and apparatus in a wireless communication system for creating a learning function
CO5180649A1 (es) 1999-09-01 2002-07-30 Abbott Lab Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes
US6803457B1 (en) * 1999-09-30 2004-10-12 Pfizer, Inc. Compounds for the treatment of ischemia
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
SK10342002A3 (sk) 2000-01-31 2003-12-02 Pfizer Products Inc. Pyrimidínkarboxamidy užitočné ako selektívne inhibítory izozymov PDE4
EE200200425A (et) 2000-01-31 2003-10-15 Pfizer Products Inc. Selektiivsete PDE4 isosüümide inhibiitoritena kasulikud nikotiinamiidi bensokondenseerunud heterotsüklüülderivaadid
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US6710086B1 (en) * 2000-02-25 2004-03-23 Medinox, Inc. Protected forms of pharmacologically active agents and uses therefor
US6753322B2 (en) * 2000-06-06 2004-06-22 Pfizer Inc 2-aminocarbonyl-9H-purine derivatives
US6921753B2 (en) * 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
GB0015727D0 (en) 2000-06-27 2000-08-16 Pfizer Ltd Purine derivatives
GB0016002D0 (en) 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
CN1678594A (zh) 2000-09-29 2005-10-05 葛兰素集团有限公司 用于治疗炎性疾病的吗啉－乙酰胺衍生物
AU2002210761A1 (en) 2000-11-03 2002-05-15 Glaxo Group Limited Method of determining susceptibility to diseases
GB0028383D0 (en) * 2000-11-21 2001-01-03 Novartis Ag Organic compounds
GB0031179D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Nitric oxide synthase inhibitors
DE10064997A1 (de) * 2000-12-23 2002-06-27 Merck Patent Gmbh Benzoylpyridazine
US6484903B2 (en) 2001-01-09 2002-11-26 Riverwood International Corporation Carton with an improved dispensing feature in combination with a unique handle
IL156704A0 (en) 2001-01-16 2004-01-04 Can Fite Biopharma Ltd Use of an adenosine a3 receptor agonist for inhibition of viral replication
US7250518B2 (en) * 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
ATE293109T1 (de) 2001-01-31 2005-04-15 Pfizer Prod Inc Nikotinsäureamid-derivate und ihre mimetika als inhibitoren von pde4-isozyms
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
GB0104555D0 (en) 2001-02-23 2001-04-11 Glaxo Group Ltd New Therapeutic method
GB2372742A (en) * 2001-03-03 2002-09-04 Univ Leiden C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
US7144908B2 (en) 2001-03-08 2006-12-05 Glaxo Group Limited Agonists of beta-adrenoceptors
WO2002072067A2 (en) 2001-03-12 2002-09-19 Glaxo Group Limited Pharmaceutical aerosol formulation
EP1370521B1 (en) 2001-03-22 2007-12-19 Glaxo Group Limited Formanilide derivatives as beta2-adrenoreceptor agonists
GEP20053675B (en) 2001-03-30 2005-11-25 Pfizer Prod Inc Pyridazinone Aldose Reductase Inhibitors
US20040204481A1 (en) * 2001-04-12 2004-10-14 Pnina Fishman Activation of natural killer cells by adenosine A3 receptor agonists
US6903109B2 (en) * 2001-04-18 2005-06-07 Ortho-Muniel Pharmaceutical, Inc. Arylindenopyridines and related therapeutic and prophylactic methods
GB0120124D0 (en) * 2001-05-04 2001-10-10 Aventis Pharm Prod Inc Effect of timing and duration of administration of amp 579 on reperfusion injury in rabbit heart
US20030013675A1 (en) 2001-05-25 2003-01-16 Boehringer Ingelheim Pharma Kg Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
BR0209986A (pt) 2001-05-25 2004-04-06 Pfizer Agonista de a2a em combinação com um agente anticolinérgico, para o tratamento de doenças obstrutivas das vias respiratórias
US20030078232A1 (en) 2001-08-08 2003-04-24 Elfatih Elzein Adenosine receptor A3 agonists
US7262176B2 (en) * 2001-08-08 2007-08-28 Cv Therapeutics, Inc. Adenosine A3 receptor agonists
MXPA04002405A (es) 2001-09-14 2004-05-31 Glaxo Group Limetd Derivados de fenetanolamina para tratamiento de enfermedades respiratorias.
WO2003029264A2 (en) 2001-10-01 2003-04-10 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
HUP0401984A3 (en) * 2001-10-31 2005-06-28 Merck Patent Gmbh Use of type 4 phosphodiesterase inhibitors for preparation of pharmaceutical compositions and combination with other active ingredients
JP2005511590A (ja) * 2001-11-02 2005-04-28 アベンティス・ファーマスーティカルズ・インコーポレイテツド アデノシンａ１／ａ２アゴニストおよびナトリウム水素交換体阻害剤を含む医薬組成物
ATE335486T1 (de) * 2001-11-05 2006-09-15 Merck Patent Gmbh Hydrazono-malonitrile
WO2003042160A1 (en) 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
US6911453B2 (en) * 2001-12-05 2005-06-28 Aventis Pharma Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them
GB0129273D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Crystalline drug form
US6703405B2 (en) * 2001-12-22 2004-03-09 Aventis Pharma Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolinium salts, process for their preparation, their use as a medicament, and medicament containing them
DE10163991A1 (de) * 2001-12-24 2003-07-03 Merck Patent Gmbh Pyrrolo-pyrimidine
ES2276038T3 (es) 2002-01-14 2007-06-16 Boehringer Ingelheim Pharmaceuticals Inc. Mimeticos de glucocorticoides, metodos para su obtencion, formulaciones farmaceuticas que los contienen y usos de los mismos.
WO2003062256A1 (en) 2002-01-17 2003-07-31 Ribapharm Inc. 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
AU2003214879B2 (en) 2002-01-22 2008-02-07 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
CA2474337A1 (en) 2002-01-25 2003-07-31 Muscagen Limited Compounds useful as a3 adenosine receptor agonists
US6756392B2 (en) * 2002-02-11 2004-06-29 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
ATE378049T1 (de) * 2002-02-11 2007-11-15 Pfizer Nicotinamid-derivate als pde4-hemmer
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
EP1486204A1 (en) 2002-03-18 2004-12-15 Yamanouchi Pharmaceutical Co. Ltd. Powdery medicinal compositions for inhalation and process for producing the same
US20040053953A1 (en) * 2002-03-18 2004-03-18 Schering Corporation Treatment of chemokine mediated diseases
GB0206657D0 (en) 2002-03-21 2002-05-01 Glaxo Group Ltd Novel intermediate and process
GB0206655D0 (en) 2002-03-21 2002-05-01 Glaxo Group Ltd Novel process
EP1490317A1 (en) 2002-03-26 2004-12-29 Boehringer Ingelheim Pharmaceuticals Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
UA80120C2 (en) 2002-03-26 2007-08-27 Boehringer Ingelheim Pharma Glucocorticoid mimetics, pharmaceutical composition based thereon
DE10215316C1 (de) 2002-04-02 2003-12-18 Schering Ag Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
EP1496892B1 (en) 2002-04-11 2011-01-26 Merck Sharp & Dohme Corp. 1h-benzo(f)indazol-5-yl derivatives as selective glucocorticoid receptor modulators
GB0208608D0 (en) 2002-04-13 2002-05-22 Glaxo Group Ltd Composition
US20040127510A1 (en) * 2002-04-16 2004-07-01 Heintzelman Geoffrey R. Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods
DE60318193T2 (de) 2002-04-25 2008-12-04 Glaxo Group Ltd., Greenford Phenethanolaminderivate
AU2003251303A1 (en) 2002-05-21 2003-12-12 Glaxo Group Limited Pharmaceutical products and methods of manufacture
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
BR0312575A (pt) 2002-07-08 2005-05-03 Pfizer Prod Inc Moduladores do receptor de glicocorticóides
WO2004009017A2 (en) 2002-07-18 2004-01-29 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
ES2337679T3 (es) 2002-07-18 2010-04-28 Bristol-Myers Squibb Company Composiciones y procedimientos que implican el sitio ii de los receptores nucleares de hormonas.
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
WO2004018429A2 (en) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US20050113302A1 (en) 2002-08-29 2005-05-26 Thompson John F. A3 receptor-mediated cardioprotective proteins and therapeutic and diagnostic methods of use
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
WO2004022573A2 (en) 2002-09-09 2004-03-18 Cv Therapeutics, Inc. Adenosine a3 receptor agonists
SI1400245T1 (sl) 2002-09-09 2006-10-31 Trigen Ltd Soli boronske kisline, uporabne v parenteralnih formulacijah za selektivno inhibiranje trombina
US20050288253A1 (en) * 2002-09-09 2005-12-29 Trigen Limited Boronic acid salts
CA2499014A1 (en) 2002-09-16 2004-03-25 Agennix Incorporated Lactoferrin compositions and methods of wound treatment
KR20050052501A (ko) 2002-09-16 2005-06-02 글락소 그룹 리미티드 피라졸로[3,4-ｂ]피리딘 화합물, 및 포스포디에스테라아제억제제로서의 이들의 용도
EP1542996A4 (en) 2002-09-20 2009-11-18 Merck & Co Inc OCTAHYDRO-2H-NAPHTOc1,2-F INDOL-4-CARBONSUUREAMIDE DERIVATIVES AS SELECTIVE MODULATORS OF THE GLUCOCORTICOID RECEPTOR
US20040229780A1 (en) * 2002-09-20 2004-11-18 Olivera Baldomero M. KappaM-conopeptides as organ protectants
AU2003270752A1 (en) 2002-09-27 2004-04-19 King Pharmaceuticals Research And Development, Inc. A method to demonstrate the efficacy of pharmacological stress agent
WO2004030621A2 (en) 2002-09-30 2004-04-15 The Trustees Of Boston University Method of treating cancer using adenosine and its analogs
MXPA05003867A (es) * 2002-10-09 2005-11-23 Schering Corp Tiadiazoldioxidos y tiadiazoloxidos como ligandos de receptor cxc-y cc-quimiocina.
US6844362B2 (en) * 2002-10-11 2005-01-18 Pfizer Inc Indole derivatives useful for the treatment of diseases
EP1407769A1 (en) 2002-10-11 2004-04-14 Pfizer Limited Indole derivatives as beta-2 agonists
WO2004032921A1 (en) 2002-10-11 2004-04-22 Pfizer Limited Indole derivatives as beta-2 agonists
WO2004037807A2 (en) 2002-10-22 2004-05-06 Glaxo Group Limited Medicinal arylethanolamine compounds
EP1578758A4 (en) 2002-10-25 2009-09-30 Us Gov Health & Human Serv PURE NUCLEOSIDES
GB0225030D0 (en) 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
ES2302956T3 (es) 2002-10-28 2008-08-01 Glaxo Group Limited Derivado de fenetanolamina para el tratamiento de enfermedades respiratorias.
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
WO2004050040A2 (en) 2002-12-03 2004-06-17 Vela Pharmaceuticals, Inc. Pharmaceutical composition of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5h-2,3-benzodiazepine and uses thereof
GB0228723D0 (en) 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
JP2006515367A (ja) 2003-01-14 2006-05-25 アルタナ　ファルマ　アクチエンゲゼルシャフト リンパ系細胞腫瘍の治療のためのｐｄｅ４阻害剤
US20040166574A1 (en) 2003-02-25 2004-08-26 Antonius John I. Microorganism
US20040175382A1 (en) * 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
GB0305153D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Identification of therapeutic compounds
GB0305149D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Compounds for the treatment of pain
GB0305150D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Use of therapeutic compounds
EP1460064A1 (en) 2003-03-14 2004-09-22 Pfizer Limited Indole-2-carboxamide derivatives useful as beta-2 agonists
US20040184995A1 (en) * 2003-03-17 2004-09-23 Yamanouchi Pharmaceutical Co., Ltd. Novel dry powder inhalation for lung-delivery and manufacturing method thereof
US20040258740A1 (en) * 2003-04-10 2004-12-23 Nene Labs Transdermal delivery composition
CA2522666A1 (en) 2003-04-18 2004-10-28 Pharmacia & Upjohn Company Llc Combination therapies for chronic obstructive pulmonary disease (copd)
EP1477167A1 (en) 2003-05-15 2004-11-17 Pfizer Limited [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists
US7268147B2 (en) * 2003-05-15 2007-09-11 Pfizer Inc Compounds useful for the treatment of diseases
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
GB0312832D0 (en) 2003-06-04 2003-07-09 Pfizer Ltd 2-amino-pyridine derivatives useful for the treatment of diseases
EP1633714B1 (en) 2003-06-04 2008-01-23 Pfizer Limited 2-amino-pyridine derivatives as beta-2 adrenoreceptor agonists
US7375100B2 (en) * 2003-06-04 2008-05-20 Pfizer Inc 2-amino-pyridine derivatives useful for the treatment of diseases
US7067541B2 (en) * 2003-06-04 2006-06-27 Pfizer Inc 2-amino-pyridine derivatives useful for the treatment of diseases
WO2004110454A1 (ja) 2003-06-13 2004-12-23 Ishihara Sangyo Kaisha, Ltd. アデノシンＡ2ａ受容体アゴニストの投与が必要な疾患を治療又は予防するための組成物
US6974862B2 (en) 2003-06-20 2005-12-13 Kensey Nash Corporation High density fibrous polymers suitable for implant
GB0317516D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as PDE4 inhibitors
US20050020587A1 (en) * 2003-07-25 2005-01-27 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
US7153870B2 (en) * 2003-07-25 2006-12-26 Pfizer Inc. Nicotinamide derivatives useful as PDE4 inhibitors
GB0317498D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Compounds
GB0317471D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Novel compounds
GB0317509D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as PDE4 inhibitors
GB0317484D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
GB0317482D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
US7132435B2 (en) * 2003-07-25 2006-11-07 Pfizer Inc. Compounds
GB0317472D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as PDE4 inhibitors
GB0317951D0 (en) 2003-07-31 2003-09-03 Trigen Ltd Compounds
NZ545979A (en) 2003-09-18 2009-02-28 King Pharmaceuticals Res & Dev Novel adenosine A3 receptor agonists

Also Published As

Publication number Publication date
AR049384A1 (es) 2006-07-26
JP2008500378A (ja) 2008-01-10
AU2005247601A1 (en) 2005-12-08
PE20060272A1 (es) 2006-05-22
MA28611B1 (fr) 2007-05-02
RU2006141276A (ru) 2008-06-27
ATE556080T1 (de) 2012-05-15
ES2383604T3 (es) 2012-06-22
WO2005116037A1 (en) 2005-12-08
BRPI0511424A (pt) 2007-12-11
US20080132526A1 (en) 2008-06-05
EP1756120A1 (en) 2007-02-28
US7737126B2 (en) 2010-06-15
EP1756120B1 (en) 2012-05-02
CA2566863A1 (en) 2005-12-08
MXPA06013627A (es) 2007-02-28
IL179009A0 (en) 2007-03-08
JP5007225B2 (ja) 2012-08-22

Similar Documents

Publication Publication Date Title
NO20065757L (no) Purinderivater
NO20074050L (no) Purinderivater som fungerer som A2A-receptoragonister
NO20072122L (no) Purinderivater for anvendelse som adenosin A-2A-reseptoragonister
NO20082000L (no) Pyrimidinamidforbindelser som PGDS-inhibitorer
NO20076450L (no) Heterosykliske forbindelser som nikotinsyrereseptoragonister for behandling av dyslipidemi
CU23497A3 (es) Derivados de triazolopiridinilsulfanilo como inhibidores de quinasa map p38
NO20064888L (no) Heterocykliske CGRP antagonister for behandling av migrene
NO20061254L (no) Farmasoytiske blandinger
BRPI0606870A2 (pt) composto de indol e uso do mesmo
NO20091244L (no) Adenosinderivater som A2A reseptoragonister
NO20090216L (no) Forbindelser med CRTH2 antagonistaktivitet
CY1113063T1 (el) Παραγωγα πουρινης για χρηση ως αγωνιστες των α2α υποδοχεων αδενοσινης
PT1252157E (pt) Carboxamidas de pirimidina uteis como inibidores de isozimas pde4
NO20090664L (no) Purinderivater som A2A-agonister
NO20076561L (no) Imidazoquinoliner som lipid kinaseinhibitorer
MX2008009413A (es) Heterociclos como agonistas del receptor de acido nicotinico para el tratamiento de la dislipidemia.
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
BRPI0514289A (pt) compostos orgánicos
NO20075113L (no) Proteinkinaseinhibitorer
EA200900472A1 (ru) Ингибиторы фосфодиэстеразы iv типа
MX2007000576A (es) Agonistas del receptor nicotinico para el tratamiento de enfermedades inflamatorias.
NO20080457L (no) Kjemiske forbindelser
NI200700039A (es) Derivados de triazolopiridinilsulfanilo como inhibidores de quinasa map p38.
NO20081483L (no) Kombinasjon av forbindelser som kan brukes ved behandling av respiratoriske sykdommer, spesielt kronisk obstruktiv pulmonaer sykdom (COPD) og astma
MXPA05012369A (es) Derivados de benzotiazol y uso de los mismos en el tratamiento de enfermedades relacionadas con el receptor a2a de adenosina.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application